| TA163 |
Ulcerative colitis (acute exacerbations) - infliximab (TA163) |
|
-
-
Infliximab for the treatment of acute exacerbations of ulcerative colitis
Infliximab is recommended as a possible treatment for people with acute, severely active ulcerative colitis only if:
- ciclosporin is considered inappropriate for them, or
- they are taking part in a research study (clinical trial)
-
Other information
How this guidance was produced
Background information
This page was last updated: 13 December 2011
-
Guidance formats
-
Implementation tools and resources
- Audit support
- Costing report
- Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology commissioning guide
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
